
Microport Cardioflow Medtech Corp
HKEX:2160

Net Margin
Microport Cardioflow Medtech Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CN |
![]() |
Microport Cardioflow Medtech Corp
HKEX:2160
|
2.1B HKD |
-14%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
232.7B USD |
32%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
191.3B USD |
28%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
157.6B USD |
12%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
150.4B USD |
12%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
110.3B USD |
14%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
51.9B EUR |
9%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
48.8B USD |
7%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
45.6B USD |
75%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.9B USD |
23%
|
|
CN |
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
274.8B CNY |
31%
|
Microport Cardioflow Medtech Corp
Glance View
MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Microport Cardioflow Medtech Corp's most recent financial statements, the company has Net Margin of -13.7%.